Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Aug 2027
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2011 to 2045.
US 7,993,832
Methods and Compositions for Diagnosing and Monitoring the Status of Transplant Rejection and Immune Disorders
Aug 14, 2027
US 11,767,559
Methods of Monitoring Immunosuppressive Therapies in a Transplant Recipient
Mar 13, 2035
US 12,790,646
Methods for Detecting, Monitoring, and Guiding Treatment of Allograft Rejection Using Discriminating Gene Expression Signatures
Jun 20, 2045
20182025203220392045
9 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2035 · High confidence
Also notable
Ends Aug 2027 · High confidence
Also notable
Ends Jun 2045 · High confidence
Methods of Monitoring Immunosuppressive Therapies in a Transplant Recipient
US 11,767,559
The most cited patent in this portfolio, cited by 91 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2035.
Methods and Compositions for Diagnosing and Monitoring the Status of Transplant Rejection and Immune Disorders
US 7,993,832
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027.
Methods for Detecting, Monitoring, and Guiding Treatment of Allograft Rejection Using Discriminating Gene Expression Signatures
US 12,790,646
Granted 2026. Too new for citation comparison; protection runs to 2045.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 26, 2027The maintenance fee for Methods of Monitoring Immunosuppressive Therapies in a Transplant Recipient (US 11,767,559) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
What they patent
The 1 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Monitoring Immunosuppressive Therapies in a Transplant Recipient | 4 in force | to Mar 2035 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,993,832 | Methods and Compositions for Diagnosing and Monitoring the Status of Transplant Rejection and Immune Disorders In force · High confidence | In force | High confidence | |
| US 11,767,559 | Methods of Monitoring Immunosuppressive Therapies in a Transplant Recipient In force · High confidence | In force | High confidence | |
| US 12,404,547 | Methods and Systems for Monitoring a Recipient of an Allograft In force · High confidence | In force | High confidence | |
| US 12,644,153 | Methods and Systems for Monitoring a Recipient of an Allograft In force · High confidence | In force | High confidence | |
| US 12,723,280 | Methods and Systems for Monitoring a Recipient of an Allograft In force · High confidence | In force | High confidence | |
| US 12,790,646 | Methods for Detecting, Monitoring, and Guiding Treatment of Allograft Rejection Using Discriminating Gene Expression Signatures In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 15 patents ended · 9 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.